))
Hold the Haldol: Exploring the Role of Cholinergics in Schizophrenia
Manage episode 287011775 series 2866905
Content provided by Daniel Fuchs, Gedaliah May, Steven Gamss, Produced by Daniel Miller, Daniel Fuchs, Gedaliah May, Steven Gamss, and Produced by Daniel Miller. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Daniel Fuchs, Gedaliah May, Steven Gamss, Produced by Daniel Miller, Daniel Fuchs, Gedaliah May, Steven Gamss, and Produced by Daniel Miller or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Until now, schizophrenia and other psychotic diseases were consistently treated with heavy duty, anti-dopaminergic, anti-psychotic medications. These drugs- both first and second generation- carry serious and sometimes irreversible adverse effects (think: EPS, NMS, etc.)
In today’s episode, we’ll discuss a groundbreaking phase-2 clinical trial exploring the use of a muscarinic agonist in the treatment of schizophrenia. Worried about DUMBBELLS? So were we! But these researchers have designed a truly elegant cholinergic/anti-cholinergic duet.
This is an exciting article you don’t want to miss out on!
27 episodes
Share
